<DOC>
	<DOCNO>NCT00664014</DOCNO>
	<brief_summary>This randomize , double-blind , multicenter , placebo-controlled ( standard therapy + placebo ) , phase 2 efficacy safety study Tolvaptan tablet treatment patient non-hypovolemic non-acute hyponatremia arise variety etiology . 240 ( 120 group ) patient enrol randomly Tolvaptan group placebo group . Subjects Tolvaptan group receive standard therapy + Tolvaptan ( 15-60mg/day ) , control group receive standard therapy + placebo . The start dose tolvaptan 15mg could titrate 30mg , necessary , maximum 60mg accord certain titration scheme base patient ' response serum sodium level . The study include 2-day screening period day -2 day -1 , 7-day inpatient study treatment ( day 1 day 7 ) . After study treatment , subject Followed-up safety event day 14 - 16 . The Primary Efficacy Variable change serum sodium baseline . For patient Congestive Heart Failure ( CHF ) hepatic cirrhosis , change body weight , fluid balance symptom improvement CHF hepatic edema assess secondary efficacy variable .</brief_summary>
	<brief_title>A Phase 2 Efficacy Safety Study Tolvaptan Tablets Patients With Non-hypovolemic Non-acute Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Hypovolemia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Informed consent . 2 . Age:18～75 ( informed consent obtain ) ，male female . 3 . Nonhypovolemic non acute hyponatremia Serum sodium &lt; 135mEq/L randomization . ( main underlying disease include CHF , hepatic cirrhosis edema , SIADH others ) 4 . Inpatient subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>hyponatremia</keyword>
	<keyword>Non-acute non hypovolemic hyponatremia</keyword>
</DOC>